These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12128165)

  • 21. Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of alphavbeta3-antagonists in rat: limited role of P-glycoprotein.
    Prueksaritanont T; Meng Y; Ma B; Leppert P; Hochman J; Tang C; Perkins J; Zrada M; Meissner R; Duggan ME; Lin JH
    Xenobiotica; 2002 Mar; 32(3):207-20. PubMed ID: 11958560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.
    Vlaming ML; Teunissen SF; van de Steeg E; van Esch A; Wagenaar E; Brunsveld L; de Greef TF; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Mol Pharmacol; 2014 Mar; 85(3):520-30. PubMed ID: 24334255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
    Collett A; Tanianis-Hughes J; Hallifax D; Warhurst G
    Pharm Res; 2004 May; 21(5):819-26. PubMed ID: 15180340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine.
    Stephens RH; Tanianis-Hughes J; Higgs NB; Humphrey M; Warhurst G
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1095-101. PubMed ID: 12438532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
    Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
    Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of platelet activating factor and the efficacy of apafant ophthalmic solution in experimental allergic conjunctivitis.
    Kato M; Kurose T; Oda T; Miyaji S
    J Ocul Pharmacol Ther; 2003 Aug; 19(4):315-24. PubMed ID: 12964956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
    Miyake T
    Biol Pharm Bull; 2020 Mar; 43(3):384-392. PubMed ID: 31685755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein.
    Bonhomme-Faivre L; Benyamina A; Reynaud M; Farinotti R; Abbara C
    Addict Biol; 2008 Sep; 13(3-4):295-300. PubMed ID: 18331373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infarct reduction by the platelet activating factor antagonist apafant in rats.
    Bielenberg GW; Wagener G; Beck T
    Stroke; 1992 Jan; 23(1):98-103. PubMed ID: 1731428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
    van Asperen J; Schinkel AH; Beijnen JH; Nooijen WJ; Borst P; van Tellingen O
    J Natl Cancer Inst; 1996 Jul; 88(14):994-9. PubMed ID: 8667431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphine antinociception is enhanced in mdr1a gene-deficient mice.
    Zong J; Pollack GM
    Pharm Res; 2000 Jun; 17(6):749-53. PubMed ID: 10955852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats.
    Akagi M; Nishioka E; Kanoh R; Tachibana M; Fukuishi N
    Arzneimittelforschung; 1997 Dec; 47(12):1364-9. PubMed ID: 9450165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of efflux transporters involved in distribution and disposition of apixaban.
    Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms.
    Yang Z; Gao S; Wang J; Yin T; Teng Y; Wu B; You M; Jiang Z; Hu M
    Drug Metab Dispos; 2011 Oct; 39(10):1866-72. PubMed ID: 21757611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
    Kivistö KT; Zukunft J; Hofmann U; Niemi M; Rekersbrink S; Schneider S; Luippold G; Schwab M; Eichelbaum M; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):124-30. PubMed ID: 15322734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.
    Saito T; Zhang ZJ; Ohtsubo T; Noda I; Shibamori Y; Yamamoto T; Saito H
    Acta Otolaryngol; 2001 Sep; 121(6):735-42. PubMed ID: 11678173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].
    Fromm MF; Kim RB; Stein CM; Wilkinson GR; Roden DM
    Circulation; 1999 Feb; 99(4):552-7. PubMed ID: 9927403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
    Elsby R; Surry DD; Smith VN; Gray AJ
    Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
    Troutman MD; Thakker DR
    Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
    Hendrikse NH; Schinkel AH; de Vries EG; Fluks E; Van der Graaf WT; Willemsen AT; Vaalburg W; Franssen EJ
    Br J Pharmacol; 1998 Aug; 124(7):1413-8. PubMed ID: 9723952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.